New hope for rare disease: drug targets stubborn Behcet's lesions

NCT ID NCT01532570

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 09, 2026 · Updated 26 times

Summary

This study tested a drug called TA-650 (similar to infliximab) in 18 people with Behcet's disease who had serious complications like eye, brain, or gut problems that didn't get better with standard treatments. The drug was given as an IV infusion at weeks 0, 2, and 6, then every 8 weeks up to week 46. The goal was to see if it could make all symptoms disappear and improve inflammation. This is a disease-control treatment, not a cure, and patients may need ongoing therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BEHCET'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Investigational site

Chūbu, Japan
Investigational site

Hokkaido, Japan
Investigational site

Kanto, Japan
Investigational site

Kinki, Japan
Investigational site

Kyusyu, Japan
Investigational site

Tōhoku, Japan

Conditions

Explore the condition pages connected to this study.

BEHCET SYNDROME BEHCET'S DISEASE NEURO-BEHCET'S DISEASE